OneDigital Investment Advisors LLC Grows Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

OneDigital Investment Advisors LLC boosted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 6.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 64,070 shares of the medical device company's stock after purchasing an additional 3,798 shares during the period. OneDigital Investment Advisors LLC's holdings in DexCom were worth $4,375,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in DXCM. Proficio Capital Partners LLC purchased a new stake in DexCom in the 4th quarter worth $5,812,000. Golden State Wealth Management LLC increased its stake in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after acquiring an additional 264 shares during the period. SBI Securities Co. Ltd. purchased a new stake in DexCom during the fourth quarter worth $49,000. Farther Finance Advisors LLC lifted its holdings in DexCom by 29.3% during the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock valued at $209,000 after purchasing an additional 702 shares in the last quarter. Finally, Dynamic Advisor Solutions LLC lifted its stake in shares of DexCom by 34.2% in the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock worth $357,000 after buying an additional 1,333 shares in the last quarter. Institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In related news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the sale, the director owned 56,621 shares of the company's stock, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 6,184 shares of the company's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the transaction, the executive vice president owned 109,621 shares of the company's stock, valued at $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,190 shares of company stock worth $2,281,732 over the last 90 days. Company insiders own 0.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on DXCM shares. Mizuho initiated coverage on shares of DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective for the company. Robert W. Baird cut their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Wall Street Zen downgraded shares of DexCom from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Citigroup reissued a "buy" rating and issued a $102.00 price target (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Finally, Truist Financial began coverage on DexCom in a research note on Monday, June 16th. They issued a "buy" rating and a $102.00 price target for the company. Five analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, DexCom has an average rating of "Moderate Buy" and a consensus target price of $98.50.

DexCom Stock Up 1.4%

NASDAQ DXCM traded up $1.16 on Wednesday, reaching $84.92. The company had a trading volume of 1,397,379 shares, compared to its average volume of 4,401,383. The company's fifty day moving average is $83.74 and its 200-day moving average is $79.90. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $117.19. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The firm has a market capitalization of $33.30 billion, a price-to-earnings ratio of 63.37, a price-to-earnings-growth ratio of 1.77 and a beta of 1.44.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the company earned $0.32 earnings per share. The firm's revenue for the quarter was up 12.5% on a year-over-year basis. On average, research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.